4 Results for "

Progeria

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Progeria" in MCE Product Catalog:

19
19 Cited Publications
Art. -Nr.: HY-16706A
CAS. Nr.: 1622921-15-6
Forschungsgebiete:  

Cancer

Remodelin hydrobromide is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin hydrobromide inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin hydrobromide inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin hydrobromide enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .
19
19 Cited Publications
Art. -Nr.: HY-16706
CAS. Nr.: 949912-58-7
Forschungsgebiete:  

Cancer

Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .
Art. -Nr.: HY-159834
CAS. Nr.: 2249696-72-6
Synonyms: SLC-D011
Target:  

DNA/RNA Synthesis

Forschungsgebiete:  

Others

Progerinin (SLC-D011) is an orally active progerin-lamin A binding inhibitor. Progerinin selectively binds to the C-terminal region of progerin, disrupting its interaction with lamin A and promoting progerin degradation while sparing wild-type lamin A, B, and C. Progerinin ameliorates nuclear deformation, increases H3K9me3 levels, and reduces progerin expression in HGPS patient-derived fibroblasts. Progerinin extends lifespan in Lmna G609G/G609G mice and Lmna G609G/+ mice, improves body weight, hair morphology, cardiac function, and histological phenotypes. Progerinin can be used for the study of Hutchinson-Gilford progeria syndrome (HGPS) .
Art. -Nr.: HY-149708
CAS. Nr.: 1621536-10-4
Reinheit:  99.61%
Target:  

ICMT

Forschungsgebiete:  

Others

UCM-13207 is a selective isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor with a human IC50 of 1.4 μM and human Ka of 7.2 μM. UCM-13207 modulates progerin localization, stability, and levels, reduces DNA damage, increases cellular viability, and decreases tissue senescence. UCM-13207 can be used for the research of Hutchinson−Gilford progeria syndrome .